Skip to content

Effect of Pamidronate on treatment of bone pains

Effect of Pamidronate on bone pains in patients with Malignancy

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013032212197N5
Enrollment
41
Registered
2013-05-05
Start date
2010-02-04
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Bone pains in Cancer patients with bone metastases. Condition 2: Hypercalcemia in Cancer patients with bone metastases. Condition 3: Quality of life in Cancer patients with bone metastases. Secondary malignant neoplasm of bone and bone marrow Disorders of calcium metabolism Lifestyle-related condition

Interventions

In this study, Pamidronic Acid Ampule (90 mg) with Pamidronate brand name (Made in Hospira company) was intravenously injected for 3 months (one per month) along with 500 mL of Normal Saline during 2-
Treatment - Drugs

Sponsors

Vice chancellor for research of Tonekabon Islamic Azad University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Malignancy with bone metastasis Exclusion criteria: Renal dysfunction history, Creatinine more than 2mg/dl, Treatment of Hypocalcemia with other Bisphosphonates

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

MeasureTime frame
Taking Sedatives. Timepoint: Before intervention - 3 months after intervention. Method of measurement: Questionnaire including Clinical data.;Taking Opiums. Timepoint: Before intervention - 3 months after intervention. Method of measurement: Questionnaire including Clinical data.

Primary

MeasureTime frame
Bone pains. Timepoint: Before intervention - 3 months after intervention. Method of measurement: Visual Analoge Scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hossein Ali Mashayekhi

Vice chancellor for research of Tonekabon Islamic Azad University

moaven.rsch.@tonekaboniau.ac.ir+98 19 2427 1105

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026